Michael E Blam, MD
Gastroenterology · Downey
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 31 years
- Washington University School of Medicine, 1995
Offices
1 location · Gastro-Digestive Medical Group · 3 clinicians in this group
Hospitals listed: Pih Health Downey Hospital · Saint Francis Medical Center · Uci Health-Lakewood. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Blam’s office at (562) 862-3656 to ask if they take your plan before you enroll.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Pih Health Downey HospitalDowney, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of PIH Health, which runs 3 hospitalsPatients rate it 3 of 5 · 73% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.157, Oct 2024 – Sep 2025
- Saint Francis Medical CenterLynwood, CAAcute Care Hospital · Voluntary non-profit - Church · No emergency department · Birthing-friendlyPart of Prime Healthcare Services, which runs 45 hospitals in 14 statesPatients rate it 2 of 5 · 62% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.228, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.055, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0, Oct 2024 – Sep 2025
- Uci Health-LakewoodLakewood, CAAcute Care Hospital · Proprietary · Has an emergency departmentPart of Tenet Healthcare, which runs 77 hospitals in 12 statesPatients rate it 1 of 5 · 48% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.105, Oct 2024 – Sep 2025
See every measure and the patient survey for Pih Health Downey Hospital
Behind the star rating — Deaths: 1 better, 5 the same, 0 worse of 6 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 4 the same, 2 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.157 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.28 (0.21 to 2.34) · 403 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.44 to 1.29) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 35 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.9 · 46 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 178 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.9 · 201 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.1 · 160 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 2,052 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.41) · 2,633 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 2,714 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.1 (0.61 to 5.59) · 276 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.66 (0 to 3.39) · 27 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.19 (0.51 to 3.87) · 273 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.89 (0 to 18.8) · 29 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (0.84 to 9.46) · 25 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.72 (0.21 to 3.24) · 63 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.29 (0 to 1.22) · 2,012 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.198 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.3 · 124 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23.1 · 614 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 3.7 · 229 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 16.5 · 234 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.8 · 495 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 86 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.6 (9.3 to 16.8) · 432 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 156 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,108 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 77% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 80% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 73% |
| Staff "always" explained possible side effects | 39% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Saint Francis Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 3 better, 3 the same, 0 worse of 6 measures. Readmissions: 1 better, 4 the same, 0 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.228 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.055 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.99 (0 to 2.05) · 378 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.82 (0.42 to 1.21) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 171.25 (124.53 to 217.98) · 45 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.9 · 37 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.3 · 65 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.5 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.3 · 218 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.6 · 1,566 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,230 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 3,280 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.98 (0.54 to 5.42) · 356 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.67 (0 to 3.4) · 34 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.13 (0.47 to 3.79) · 343 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.03 (0 to 19.03) · 39 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.11 (0.82 to 9.39) · 35 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.27) · 38 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.19 (0 to 0.92) · 2,725 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.436 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.183 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 195 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 370 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -36.8 · 57 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -26.7 · 196 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -11.8 · 215 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 364 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.4 · 92 cases | None | Jul 2023 – Jun 2025 |
What patients said (575 patients answered, 34% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 77% |
| Nurses "always" communicated well | 70% |
| Doctors "always" communicated well | 70% |
| Staff "always" explained | 52% |
| Yes, staff "did" give patients this information | 81% |
| Yes, staff "did" give patients information about help after discharge | 79% |
| Doctors "always" explained things so they could understand | 64% |
| Doctors "always" listened carefully | 68% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 65% |
| Staff "always" explained new medications | 66% |
| Nurses "always" explained things so they could understand | 65% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 79% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 62% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
See every measure and the patient survey for Uci Health-Lakewood
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 6 the same, 2 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.105 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.94 (0 to 1.97) · 512 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.15 (0.77 to 1.53) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.76 (139.14 to 246.38) · 35 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 27 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 57 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.5 · 56 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.8 · 149 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.2 · 264 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 14.5 · 223 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 1,866 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.07 to 0.51) · 3,098 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.07 to 0.48) · 3,262 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.72 (1.33 to 6.11) · 498 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.91 (1.29 to 4.53) · 492 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.25 (1.53 to 20.97) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.71 (0.2 to 3.22) · 80 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.91 (0.24 to 1.58) · 2,875 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.2 · 89 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.584 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.28 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.498 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.265 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.5 · 181 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.3 · 403 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.3 · 56 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 32.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 89.6 · 289 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 495 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 96 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12 · 70 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.7 · 111 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (9.5 to 17.5) · 95 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.2) · 80 cases | No different | Jan 2024 – Dec 2024 |
What patients said (391 patients answered, 15% of those asked)
| Cleanliness | 3 |
| Nurse communication | 1 |
| Doctor communication | 1 |
| Communication about medicines | 1 |
| Discharge information | 2 |
| Overall hospital rating | 1 |
| Quietness | 1 |
| Recommend hospital | 1 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 66% |
| Doctors "always" communicated well | 68% |
| Staff "always" explained | 50% |
| Yes, staff "did" give patients this information | 79% |
| Yes, staff "did" give patients information about help after discharge | 78% |
| Doctors "always" explained things so they could understand | 62% |
| Doctors "always" listened carefully | 67% |
| Doctors "always" treated them with courtesy and respect | 75% |
| Patients who gave a rating of "9" or "10" (high) | 49% |
| Staff "always" explained new medications | 63% |
| Nurses "always" explained things so they could understand | 60% |
| Nurses "always" listened carefully | 64% |
| Nurses "always" treated them with courtesy and respect | 73% |
| "Always" quiet at night | 33% |
| "YES", patients would definitely recommend the hospital | 48% |
| Staff "always" explained possible side effects | 36% |
| Yes, staff "did" give patients information about possible symptoms | 80% |
Original Medicare doctor bills
$148,687
Medicare paid this office $148,687 for 558 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 387 | $77,558 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 289 | $41,433 | $134 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 84 | $8,142 | $95 |
| Insertion of stomach tube using a flexible endoscope | 19 | $2,937 | $155 |
| Biopsy of large bowel using a flexible endoscope | 22 | $2,667 | $121 |
See all 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 387 | $77,558 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 289 | $41,433 | $134 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 84 | $8,142 | $95 |
| Insertion of stomach tube using a flexible endoscope | 19 | $2,937 | $155 |
| Biopsy of large bowel using a flexible endoscope | 22 | $2,667 | $121 |
| Diagnostic exam of large bowel using a flexible endoscope | 23 | $2,531 | $110 |
| New patient visit (30+ min) | 26 | $2,183 | $84 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 17 | $1,583 | $93 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,559 | $142 |
| Short return visit (20+ min) | 11 | $1,043 | $74 |
Procedures Medicare counted
| Colonoscopy | 94 | More than 78% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 200 | More than 90% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 63 | 53 | 71 | 79 | 103 | 86 |
| Diagnostic exam of large bowel using a flexible endoscope | 39 | 22 | 20 | 28 | 38 | 23 |
| Biopsy of large bowel using a flexible endoscope | 21 | 19 | 14 | 19 | 27 | 22 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 41 | 15 | 12 | 13 | 23 | 17 |
| Insertion of stomach tube using a flexible endoscope | – | 14 | – | 12 | 18 | 19 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | – | – | – | – | – | 11 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
558 Original Medicare patients in 2024. Average age 73 · Under 65 17% · 85 and older 17% · Women 54% · Also on Medicaid 88% · Health risk score 4.18. Sicker patients than 9 in 10 peers; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 75% · Diabetes 73% · Chronic kidney disease 64% · Heart failure 60% · Coronary heart disease 52% · Depression 41% · Dementia 37% · COPD 36% · Atrial fibrillation 36% · Stroke 30% · Cancer 17%.
The office billed $497,503, Medicare allowed $189,021 and paid $148,687; for 1,843 services of 27 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 558 | 1,843 | 73 | 4.18 | $497,503 | $148,687 |
| 2023 | 469 | 1,360 | 73 | 3.93 | $453,554 | $125,106 |
| 2022 | 402 | 1,079 | 72 | 3.62 | $339,908 | $98,725 |
| 2021 | 414 | 1,234 | 72 | 3.62 | $337,696 | $107,423 |
| 2020 | 401 | 1,350 | 74 | 3.54 | $358,863 | $116,969 |
| 2019 | 468 | 1,552 | 72 | 3.98 | $430,046 | $132,371 |
| 2018 | 414 | 1,040 | 73 | 3.80 | $195,249 | $93,892 |
| 2017 | 470 | 1,289 | 72 | 4.00 | $206,549 | $117,668 |
| 2016 | 218 | 635 | 71 | 4.09 | $104,985 | $57,241 |
| 2015 | 15 | 30 | 67 | 1.07 | $3,874 | $1,413 |
| 2014 | 56 | 101 | 66 | 1.48 | $26,921 | $9,917 |
| 2013 | 55 | 91 | 66 | 1.70 | $29,693 | $12,372 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 263 | $48,448 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 253 | $39,067 | $141 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 102 | $9,844 | $96 |
| Diagnostic exam of large bowel using a flexible endoscope | 37 | $4,968 | $131 |
| Biopsy of large bowel using a flexible endoscope | 27 | $3,776 | $140 |
| New patient visit (30+ min) | 38 | $3,477 | $91 |
| Insertion of stomach tube using a flexible endoscope | 18 | $2,812 | $156 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 23 | $2,136 | $93 |
| Short return visit (20+ min) | 16 | $1,292 | $76 |
2022: 9 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 216 | $36,867 | $160 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 237 | $36,375 | $58 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 78 | $7,650 | $97 |
| Diagnostic exam of large bowel using a flexible endoscope | 27 | $4,255 | $152 |
| New patient visit (30+ min) | 28 | $2,546 | $91 |
| Biopsy of large bowel using a flexible endoscope | 19 | $2,501 | $132 |
| Insertion of stomach tube using a flexible endoscope | 12 | $1,969 | $164 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,265 | $97 |
| Short return visit (20+ min) | 14 | $1,075 | $77 |
2021: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 274 | $48,397 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 199 | $36,364 | $165 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 70 | $7,502 | $106 |
| Diagnostic exam of large bowel using a flexible endoscope | 20 | $3,102 | $155 |
| New patient visit (30+ min) | 29 | $2,651 | $91 |
| Biopsy of large bowel using a flexible endoscope | 14 | $2,045 | $146 |
| Short return visit (20+ min) | 22 | $1,752 | $73 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $1,185 | $99 |
2020: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 263 | $55,282 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 202 | $37,813 | $168 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 51 | $5,500 | $104 |
| Diagnostic exam of large bowel using a flexible endoscope | 22 | $3,399 | $155 |
| New patient visit (30+ min) | 33 | $2,935 | $89 |
| Biopsy of large bowel using a flexible endoscope | 19 | $2,927 | $154 |
| Insertion of stomach tube using a flexible endoscope | 14 | $2,376 | $170 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | $1,567 | $104 |
| Short return visit (20+ min) | 19 | $1,240 | $59 |
2019: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 297 | $60,220 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 247 | $43,817 | $163 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 63 | $6,231 | $99 |
| Diagnostic exam of large bowel using a flexible endoscope | 38 | $5,841 | $150 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 41 | $4,136 | $101 |
| Biopsy of large bowel using a flexible endoscope | 20 | $3,504 | $167 |
| New patient visit (30+ min) | 33 | $2,875 | $87 |
| Short return visit (20+ min) | 21 | $1,543 | $62 |
2018: 8 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 220 | $39,420 | $159 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 267 | $34,648 | $57 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 38 | $4,042 | $104 |
| Diagnostic exam of large bowel using a flexible endoscope | 22 | $3,043 | $138 |
| Biopsy of large bowel using a flexible endoscope | 18 | $2,576 | $143 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 25 | $2,544 | $98 |
| New patient visit (30+ min) | 28 | $2,221 | $79 |
| Short return visit (20+ min) | 17 | $1,183 | $56 |
2017: 8 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 282 | $51,006 | $163 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 332 | $47,123 | $58 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 40 | $4,693 | $102 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 32 | $3,510 | $110 |
| Diagnostic exam of large bowel using a flexible endoscope | 17 | $2,731 | $152 |
| Biopsy of large bowel using a flexible endoscope | 13 | $1,875 | $144 |
| New patient visit (30+ min) | 13 | $919 | $71 |
| Short return visit (20+ min) | 13 | $908 | $57 |
2016: 4 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 131 | $23,159 | $163 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 159 | $22,806 | $58 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 34 | $3,653 | $104 |
| New patient visit (30+ min) | 13 | $1,154 | $89 |
2014: 2 services
| Return visit (30+ min) | 15 | $1,655 | $87 |
| Short return visit (20+ min) | 11 | $687 | $62 |
2013: 2 services
| Long return visit (40+ min) | 16 | $2,183 | $121 |
| Return visit (30+ min) | 13 | $1,165 | $83 |
Medicaid work
$100,305 in 2024
Medicaid paid $100,305 for 1,827 billed services this clinician did in 2024, up to 52 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| 1ST HOSP IP/OBS HIGH 75 | 436 | $21,190 |
| Upper gastrointestinal endoscopy with biopsy | 185 | $21,033 |
| DIAGNOSTIC COLONOSCOPY | 110 | $20,740 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 506 | $9,863 |
| New patient visit (45+ min) | 191 | $9,536 |
| COLONOSCOPY AND BIOPSY | 43 | $7,422 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intraservice time, patient age 5 years or older | 60 | $3,639 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 66 | $2,544 |
| Injection, midazolam hydrochloride, per 1 mg | 79 | $2,114 |
| New patient visit (30+ min) | 31 | $968 |
| TISSUE EXAM BY PATHOLOGIST | 15 | $639 |
| Fentanyl citrate injection | 79 | $588 |
| 2024 | 1,827 | 13 | 52 | $100,305 |
| 2023 | 2,971 | 15 | 63 | $194,733 |
| 2022 | 4,222 | 21 | 48 | $277,248 |
| 2021 | 4,590 | 19 | 66 | $240,785 |
| 2020 | 2,624 | 17 | 47 | $132,008 |
| 2019 | 2,855 | 12 | 44 | $144,729 |
| 2018 | 2,028 | 11 | 38 | $56,699 |
See the largest Medicaid services in earlier years
2023
| DIAGNOSTIC COLONOSCOPY | 266 | $48,397 |
| Upper gastrointestinal endoscopy with biopsy | 341 | $38,694 |
| 1ST HOSP IP/OBS HIGH 75 | 464 | $29,248 |
| COLONOSCOPY AND BIOPSY | 89 | $16,663 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intraservice time, patient age 5 years or older | 209 | $12,030 |
| New patient visit (30+ min) | 228 | $11,268 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 325 | $8,641 |
| TISSUE EXAM BY PATHOLOGIST | 152 | $6,960 |
| Injection, midazolam hydrochloride, per 1 mg | 239 | $6,112 |
| New patient visit (45+ min) | 82 | $5,825 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 96 | $4,666 |
| Short return visit (20+ min) | 116 | $3,220 |
2022
| DIAGNOSTIC COLONOSCOPY | 334 | $69,368 |
| Upper gastrointestinal endoscopy with biopsy | 382 | $47,512 |
| COLONOSCOPY AND BIOPSY | 205 | $43,308 |
| 1ST HOSP IP/OBS HIGH 75 | 422 | $31,746 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 683 | $17,703 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intraservice time, patient age 5 years or older | 267 | $15,566 |
| New patient visit (30+ min) | 281 | $15,254 |
| Injection, midazolam hydrochloride, per 1 mg | 288 | $6,817 |
| New patient visit (45+ min) | 99 | $5,451 |
| TISSUE EXAM BY PATHOLOGIST | 168 | $5,411 |
| Short return visit (20+ min) | 175 | $4,281 |
| Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique | 65 | $4,259 |
2021
| DIAGNOSTIC COLONOSCOPY | 292 | $43,966 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 1,324 | $40,367 |
| Upper gastrointestinal endoscopy with biopsy | 315 | $35,586 |
| 1ST HOSP IP/OBS HIGH 75 | 433 | $34,977 |
| COLONOSCOPY AND BIOPSY | 118 | $19,094 |
| New patient visit (30+ min) | 422 | $15,548 |
| Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique | 196 | $15,388 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intraservice time, patient age 5 years or older | 196 | $10,810 |
| Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 54 | $5,888 |
| Injection, midazolam hydrochloride, per 1 mg | 283 | $5,429 |
| TISSUE EXAM BY PATHOLOGIST | 162 | $4,395 |
| Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 114 | $2,931 |
2020
| DIAGNOSTIC COLONOSCOPY | 166 | $26,284 |
| Upper gastrointestinal endoscopy with biopsy | 220 | $25,170 |
| 1ST HOSP IP/OBS HIGH 75 | 381 | $24,767 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 754 | $20,815 |
| COLONOSCOPY AND BIOPSY | 96 | $15,462 |
| New patient visit (30+ min) | 308 | $7,593 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intraservice time, patient age 5 years or older | 60 | $3,042 |
| Injection, midazolam hydrochloride, per 1 mg | 138 | $2,581 |
| TISSUE EXAM BY PATHOLOGIST | 78 | $1,903 |
| Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 21 | $1,878 |
| Fentanyl citrate injection | 130 | $915 |
| Short return visit (20+ min) | 94 | $592 |
2019
| DIAGNOSTIC COLONOSCOPY | 352 | $44,266 |
| COLONOSCOPY AND BIOPSY | 167 | $26,789 |
| Upper gastrointestinal endoscopy with biopsy | 292 | $24,249 |
| 1ST HOSP IP/OBS HIGH 75 | 322 | $18,820 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 765 | $16,095 |
| New patient visit (30+ min) | 349 | $8,316 |
| TISSUE EXAM BY PATHOLOGIST | 74 | $1,607 |
| Injection, midazolam hydrochloride, per 1 mg | 206 | $1,505 |
| Short return visit (20+ min) | 109 | $1,045 |
| New patient visit (45+ min) | 15 | $1,034 |
| Fentanyl citrate injection | 192 | $908 |
| Infusion, normal saline solution , 1000 cc | 12 | $95 |
2018
| DIAGNOSTIC COLONOSCOPY | 163 | $15,509 |
| Upper gastrointestinal endoscopy with biopsy | 164 | $10,690 |
| 1ST HOSP IP/OBS HIGH 75 | 246 | $9,654 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 509 | $8,947 |
| TISSUE EXAM BY PATHOLOGIST | 238 | $4,244 |
| New patient visit (30+ min) | 192 | $3,572 |
| Injection, midazolam hydrochloride, per 1 mg | 225 | $1,518 |
| New patient visit (45+ min) | 17 | $1,102 |
| Fentanyl citrate injection | 181 | $792 |
| Short return visit (20+ min) | 74 | $603 |
| Unclassified drugs | 19 | $68 |
Drugs they prescribed that Part D paid
$123,420
Pharmacies billed $123,420 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 785) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
614 generic and 171 brand-name prescriptions · $123,420 in drug cost · 27 antibiotic prescriptions to 16 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Linzess | 80 | $43,771 | $547 |
| Sod Sulf-Potass Sulf-Mag Sulf | 135 | $7,521 | $56 |
| Mesalamine | 20 | $4,554 | $228 |
| Sucralfate | 18 | $3,597 | $200 |
| Gavilyte-G | 133 | $1,751 | $13 |
See all 15 drugs
| Linzess | 80 | $43,771 | $547 |
| Sod Sulf-Potass Sulf-Mag Sulf | 135 | $7,521 | $56 |
| Mesalamine | 20 | $4,554 | $228 |
| Sucralfate | 18 | $3,597 | $200 |
| Gavilyte-G | 133 | $1,751 | $13 |
| Loperamide | 15 | $1,097 | $73 |
| Dicyclomine | 69 | $1,025 | $15 |
| Pantoprazole | 99 | $737 | $7 |
| Peg-3350 and Electrolytes | 50 | $665 | $13 |
| Ondansetron Odt | 15 | $542 | $36 |
| Hydrocortisone | 16 | $291 | $18 |
| Gavilyte-C | 14 | $268 | $19 |
| Famotidine | 13 | $167 | $13 |
| Lansoprazole | 14 | $131 | $9 |
| Omeprazole | 17 | $72 | $4 |
Year by year
| 2024 | 785 | 440 | 0% (0) | 22% | $123,420 |
| 2023 | 837 | 451 | 0% (0) | 19% | $121,067 |
| 2022 | 798 | 422 | 0% (0) | None | $241,035 |
| 2021 | 981 | 463 | 0% (0) | 34% | $212,547 |
| 2020 | 1,098 | 470 | 0% (0) | None | $335,412 |
| 2019 | 1,126 | 546 | 0% (0) | 31% | $325,246 |
| 2018 | 758 | 437 | 0% (0) | 42% | $315,143 |
| 2017 | 590 | 354 | 0% (0) | 38% | $408,362 |
| 2016 | 402 | 238 | 0% (0) | None | $496,433 |
| 2015 | 448 | 217 | 0% (0) | 50% | $617,339 |
| 2014 | 374 | 152 | 0% (0) | None | $194,753 |
| 2013 | 371 | 178 | 0% (0) | None | $53,146 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Linzess | 75 | $41,729 | $556 |
| Mesalamine | 20 | $12,753 | $638 |
| Sod Sulf-Potass Sulf-Mag Sulf | 124 | $8,828 | $71 |
| Gavilyte-G | 181 | $2,916 | $16 |
| Sucralfate | 31 | $2,799 | $90 |
| Suprep | 22 | $2,186 | $99 |
| Dicyclomine | 85 | $1,761 | $21 |
| Loperamide | 15 | $1,534 | $102 |
| Ursodiol | 21 | $1,512 | $72 |
| Pantoprazole | 106 | $1,112 | $10 |
| Procto-Med Hc | 13 | $731 | $56 |
| Famotidine | 26 | $709 | $27 |
| Ondansetron Odt | 13 | $656 | $50 |
| Hydrocortisone | 15 | $532 | $35 |
| Omeprazole | 16 | $296 | $19 |
| Peg-3350 and Electrolytes | 18 | $274 | $15 |
| Gavilyte-C | 13 | $192 | $15 |
2022: 14 drugs
| Linzess | 68 | $38,664 | $569 |
| Mesalamine | 26 | $17,113 | $658 |
| Suprep | 102 | $11,287 | $111 |
| Sucralfate | 35 | $4,026 | $115 |
| Dicyclomine | 88 | $2,552 | $29 |
| Gavilyte-G | 116 | $1,611 | $14 |
| Sod Sulf-Potass Sulf-Mag Sulf | 18 | $1,486 | $83 |
| Pantoprazole | 110 | $945 | $9 |
| Loperamide | 17 | $906 | $53 |
| Peg-3350 and Electrolytes | 54 | $798 | $15 |
| Procto-Med Hc | 15 | $564 | $38 |
| Omeprazole | 24 | $211 | $9 |
| Gavilyte-C | 11 | $170 | $15 |
| Famotidine | 14 | $168 | $12 |
2021: 19 drugs
| Xifaxan | 32 | $79,855 | $2,495 |
| Linzess | 83 | $40,396 | $487 |
| Mesalamine | 38 | $22,826 | $601 |
| Suprep | 165 | $17,642 | $107 |
| Sucralfate | 48 | $5,536 | $115 |
| Dicyclomine | 154 | $4,619 | $30 |
| Pantoprazole | 91 | $1,135 | $12 |
| Loperamide | 18 | $703 | $39 |
| Peg 3350-Electrolyte | 38 | $688 | $18 |
| Gavilyte-G | 45 | $578 | $13 |
| Proctosol-Hc | 15 | $558 | $37 |
| Omeprazole | 63 | $510 | $8 |
| Clarithromycin | 12 | $482 | $40 |
| Peg-3350 and Electrolytes | 31 | $394 | $13 |
| Ondansetron | 11 | $203 | $18 |
| Lansoprazole | 14 | $196 | $14 |
| Gavilyte-C | 13 | $171 | $13 |
| Propranolol | 15 | $127 | $8 |
| Amoxicillin | 13 | $115 | $9 |
2020: 16 drugs
| Xifaxan | 46 | $113,160 | $2,460 |
| Linzess | 132 | $61,513 | $466 |
| Suprep | 127 | $13,045 | $103 |
| Sucralfate | 78 | $8,292 | $106 |
| Mesalamine | 12 | $5,710 | $476 |
| Amitiza | 14 | $5,026 | $359 |
| Dicyclomine | 117 | $2,796 | $24 |
| Gavilyte-G | 113 | $1,599 | $14 |
| Hydrocortisone | 17 | $1,348 | $79 |
| Omeprazole | 89 | $1,057 | $12 |
| Pantoprazole | 116 | $825 | $7 |
| Proctosol-Hc | 22 | $787 | $36 |
| Ondansetron | 17 | $722 | $42 |
| Peg-3350 and Electrolytes | 34 | $420 | $12 |
| Gavilyte-C | 29 | $386 | $13 |
| Peg 3350-Electrolyte | 11 | $132 | $12 |
2019: 18 drugs
| Xifaxan | 22 | $44,599 | $2,027 |
| Linzess | 81 | $39,662 | $490 |
| Moviprep | 84 | $8,874 | $106 |
| Clenpiq | 31 | $4,176 | $135 |
| Suprep | 42 | $4,039 | $96 |
| Sucralfate | 100 | $2,798 | $28 |
| Gavilyte-G | 170 | $2,342 | $14 |
| Dicyclomine | 75 | $1,390 | $19 |
| Omeprazole | 136 | $1,382 | $10 |
| Proctosol-Hc | 27 | $891 | $33 |
| Pantoprazole | 103 | $749 | $7 |
| Proctozone-Hc | 15 | $737 | $49 |
| Hydrocortisone | 11 | $491 | $45 |
| Ondansetron Odt | 19 | $473 | $25 |
| Clarithromycin | 14 | $408 | $29 |
| Gavilyte-C | 31 | $404 | $13 |
| Peg-3350 and Electrolytes | 27 | $344 | $13 |
| Amoxicillin | 15 | $79 | $5 |
2018: 14 drugs
| Linzess | 47 | $25,019 | $532 |
| Suprep | 149 | $13,737 | $92 |
| Carafate | 12 | $4,620 | $385 |
| Clenpiq | 23 | $2,974 | $129 |
| Ursodiol | 11 | $2,267 | $206 |
| Sucralfate | 50 | $1,567 | $31 |
| Gavilyte-G | 98 | $1,347 | $14 |
| Proctozone-Hc | 14 | $922 | $66 |
| Omeprazole | 87 | $885 | $10 |
| Pantoprazole | 59 | $396 | $7 |
| Peg-3350 and Electrolytes | 28 | $339 | $12 |
| Gavilyte-C | 21 | $307 | $15 |
| Dicyclomine | 29 | $297 | $10 |
| Peg 3350-Electrolyte | 11 | $122 | $11 |
2017: 9 drugs
| Linzess | 19 | $7,462 | $393 |
| Suprep | 25 | $2,372 | $95 |
| Peg-3350 and Electrolytes | 122 | $1,506 | $12 |
| Gavilyte-G | 107 | $1,459 | $14 |
| Omeprazole | 97 | $819 | $8 |
| Sucralfate | 18 | $347 | $19 |
| Dicyclomine | 23 | $325 | $14 |
| Pantoprazole | 30 | $236 | $8 |
| Gavilyte-C | 15 | $218 | $15 |
2016: 9 drugs
| Harvoni | 11 | $350,620 | $31,875 |
| Moviprep | 37 | $3,259 | $88 |
| Peg-3350 and Electrolytes | 63 | $783 | $12 |
| Pantoprazole | 25 | $527 | $21 |
| Omeprazole | 47 | $518 | $11 |
| Gavilyte-G | 35 | $460 | $13 |
| Dicyclomine | 12 | $218 | $18 |
| Gavilyte-C | 14 | $167 | $12 |
| Peg 3350-Electrolyte | 15 | $160 | $11 |
2015: 10 drugs
| Harvoni | 17 | $538,123 | $31,654 |
| Humira | 11 | $35,488 | $3,226 |
| Moviprep | 91 | $7,387 | $81 |
| Rabeprazole | 12 | $966 | $80 |
| Omeprazole | 56 | $841 | $15 |
| Pantoprazole | 38 | $801 | $21 |
| Balsalazide Disodium | 11 | $477 | $43 |
| Polyethylene Glycol 3350 | 12 | $342 | $29 |
| Peg-3350 and Electrolytes | 24 | $318 | $13 |
| Peg 3350-Electrolyte | 24 | $257 | $11 |
2014: 11 drugs
| Xifaxan | 16 | $22,627 | $1,414 |
| Moviprep | 54 | $4,337 | $80 |
| Linzess | 14 | $3,508 | $251 |
| Omeprazole | 63 | $1,176 | $19 |
| Rabeprazole | 15 | $1,023 | $68 |
| Pantoprazole | 23 | $529 | $23 |
| Balsalazide Disodium | 12 | $465 | $39 |
| Peg-3350 and Electrolytes | 27 | $361 | $13 |
| Peg 3350-Electrolyte | 27 | $305 | $11 |
| Lactulose | 13 | $112 | $9 |
| Azathioprine | 12 | $100 | $8 |
2013: 10 drugs
| Xifaxan | 19 | $24,225 | $1,275 |
| Amitiza | 11 | $4,364 | $397 |
| Moviprep | 26 | $1,859 | $72 |
| Omeprazole | 56 | $896 | $16 |
| Peg-3350 and Electrolytes | 53 | $804 | $15 |
| Pantoprazole | 27 | $526 | $19 |
| Peg 3350-Electrolyte | 32 | $379 | $12 |
| Gavilyte-C | 12 | $161 | $13 |
| Azathioprine | 12 | $124 | $10 |
| Ranitidine | 11 | $107 | $10 |
Money from drug and device companies
$656 in 2025
| 2025 | 5 | 43 | None | $656 |
| 2024 | 3 | 5 | None | $99 |
| 2023 | 2 | 5 | None | $84 |
| 2022 | 4 | 13 | None | $265 |
| 2021 | 2 | 7 | None | $134 |
| 2020 | 3 | 26 | None | $583 |
| 2019 | 3 | 15 | None | $243 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $282 | 26 payments
|
| Ardelyx | Ibsrela | $272 | 13 payments
|
| Janssen Biotech | Tremfya | $47 | 2 payments
|
| Pfizer | Velsipity | $29 | 1 payment
|
| Madrigal Pharmaceuticals | Rezdiffra | $26 | 1 payment
|
See all 43 published payments
| Ardelyx | Meals · 2025-12-16 | Ibsrela | $11 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-12-15 | Xifaxan | $11 |
| Ardelyx | Meals · 2025-12-15 | Ibsrela | $22 |
| Ardelyx | Meals · 2025-12-15 | Ibsrela | $4 |
| Ardelyx | Meals · 2025-12-05 | Ibsrela | $28 |
| Ardelyx | Meals · 2025-11-19 | Ibsrela | $19 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-11-18 | Xifaxan | $21 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-11-18 | Xifaxan | $5 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-11-18 | Xifaxan | $5 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-11-18 | Xifaxan | $11 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-10-14 | Xifaxan | $19 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-10-14 | Xifaxan | $13 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-10-14 | Xifaxan | $8 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-10-14 | Xifaxan | $8 |
| Pfizer | Meals · 2025-10-13 | Velsipity | $29 |
| Ardelyx | Meals · 2025-10-03 | Ibsrela | $20 |
| Ardelyx | Meals · 2025-10-02 | Ibsrela | $26 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-09-24 | Xifaxan | $9 |
| Ardelyx | Meals · 2025-09-11 | Ibsrela | $12 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-09-02 | Xifaxan | $4 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-09-02 | Xifaxan | $7 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-09-02 | Xifaxan | $10 |
| Janssen Biotech | Meals · 2025-08-15 | Tremfya | $20 |
| Ardelyx | Meals · 2025-07-07 | Ibsrela | $25 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-06-30 | Xifaxan | $20 |
| Ardelyx | Meals · 2025-06-23 | Ibsrela | $27 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-06-03 | Xifaxan | $14 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-06-03 | Xifaxan | $8 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-06-03 | Xifaxan | $16 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-06-03 | Xifaxan | $10 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-06-03 | Xifaxan | $15 |
| Madrigal Pharmaceuticals | Meals · 2025-05-22 | Rezdiffra | $26 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-05-12 | Xifaxan | $18 |
| Ardelyx | Meals · 2025-04-17 | Ibsrela | $30 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-03-28 | Xifaxan | $3 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-03-28 | Xifaxan | $20 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-03-28 | Xifaxan | $7 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-03-28 | Xifaxan | $7 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-02-28 | Xifaxan | $6 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-02-28 | Xifaxan | $9 |
| Ardelyx | Meals · 2025-02-12 | Ibsrela | $32 |
| Janssen Biotech | Meals · 2025-02-07 | Tremfya | $27 |
| Ardelyx | Meals · 2025-01-17 | Ibsrela | $15 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $99
| Merck Sharp & Dohme | Dificid | $52 | 3 payments
|
| Shield Therapeutics | Accrufer | $31 | 1 payment
|
| Ardelyx | Ibsrela | $16 | 1 payment
|
2023: $84
| Merck Sharp & Dohme | Dificid | $69 | 4 payments
|
| RedHill Biopharma | Talicia | $16 | 1 payment
|
2022: $265
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $187 | 8 payments
|
| Abbvie | Mavyret | $36 | 2 payments
|
| RedHill Biopharma | Talicia | $27 | 2 payments
|
| Merck Sharp & Dohme | Dificid | $15 | 1 payment
|
2021: $134
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $118 | 6 payments
|
| Merck Sharp & Dohme | Dificid | $16 | 1 payment
|
2020: $583
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $545 | 24 payments
|
| Ferring Pharmaceuticals | Clenpiq | $19 | 1 payment
|
| RedHill Biopharma | Talicia | $19 | 1 payment
|
2019: $243
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $187 | 12 payments
|
| Gilead Sciences | None | $38 | 2 payments
|
| Ferring Pharmaceuticals | Clenpiq | $18 | 1 payment
|
Professional record
- NPI
- 1801877733
- Licence
- CT 039355
- Trained
- Washington University School of Medicine, 1995 · 31 years ago
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CT 001393553
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 2925 Palo Verde Ave, Long Beach, CA, 90815
- NPI first listed
- 2005-11-08
- NPI last updated
- 2013-01-29
This is when the NPI record was last certified, not a medical board exam.